177 related articles for article (PubMed ID: 3281516)
1. Effects of naftidrofuryl in patients with intermittent claudication.
Karnik R; Valentin A; Stöllberger C; Slany J
Angiology; 1988 Mar; 39(3 Pt 1):234-40. PubMed ID: 3281516
[TBL] [Abstract][Full Text] [Related]
2. Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using Naftidrofuryl tablets 200 mg.
Adhoute G; Bacourt F; Barral M; Cardon JM; Chevalier JM; Cuny A; Gillet M; Juhan C; Leguay G; Marion J
Angiology; 1986 Mar; 37(3 Pt 1):160-7. PubMed ID: 3518547
[TBL] [Abstract][Full Text] [Related]
3. Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study.
Adhoute G; Andreassian B; Boccalon H; Cloarec M; Di Maria G; Lefebvre O; Mondine P; Plagnol P; Pointel JP; Quancard X
J Cardiovasc Pharmacol; 1990; 16 Suppl 3():S75-80. PubMed ID: 1369725
[TBL] [Abstract][Full Text] [Related]
4. A controlled trial of naftidrofuryl (Praxilene) in the treatment of intermittent claudication.
Clyne CA; Galland RB; Fox MJ; Gustave R; Jantet GH; Jamieson CW
Br J Surg; 1980 May; 67(5):347-8. PubMed ID: 6992909
[TBL] [Abstract][Full Text] [Related]
5. [Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication].
Boccalon H; Lehert P; Mosnier M
Ann Cardiol Angeiol (Paris); 2001 Apr; 50(3):175-82. PubMed ID: 12555510
[TBL] [Abstract][Full Text] [Related]
6. Effects of regular physical training in a supervised class and additional intravenous prostaglandin E1 and naftidrofuryl infusion therapy in patients with intermittent claudication--a controlled study.
Diehm C; Kühn A; Strauss R; Hübsch-Müller C; Kübler W
Vasa Suppl; 1989; 28():26-30. PubMed ID: 2609241
[TBL] [Abstract][Full Text] [Related]
7. The effect of naftidrofuryl (Praxilene) on intermittent claudication.
Waters KJ; Craxford AD; Chamberlain J
Br J Surg; 1980 May; 67(5):349-51. PubMed ID: 6992910
[TBL] [Abstract][Full Text] [Related]
8. Naftidrofuryl in chronic arterial disease. Results of a controlled multicenter study.
Trübestein G; Böhme H; Heidrich H; Heinrich F; Hirche H; Maass U; Mörl H; Rudofsky G
Angiology; 1984 Nov; 35(11):701-8. PubMed ID: 6388425
[TBL] [Abstract][Full Text] [Related]
9. [Naftidrofuryl in arterial occlusive disease. Controlled multicenter double-blind study with oral administration].
Maass U; Amberger HG; Böhme H; Diehm C; Dimroth H; Heidrich H; Heinrich F; Hirche H; Mörl H; Müller-Bühl U
Dtsch Med Wochenschr; 1984 May; 109(19):745-50. PubMed ID: 6373217
[TBL] [Abstract][Full Text] [Related]
10. [Naftidrofuryl in the therapy of chronic arterial occlusive disease in the intermittent claudication stage].
Valentin A; Karnik R; Stöllberger C; Slany J
Vasa Suppl; 1987; 20():361-4. PubMed ID: 3321493
[No Abstract] [Full Text] [Related]
11. Comparison of safety and efficacy of buflomedil and naftidrofuryl in the treatment of intermittent claudication.
Rosas G; Cerdeyra C; Lucas MA; Parano JR; Villa JJ
Angiology; 1981 May; 32(5):291-7. PubMed ID: 7235299
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl.
Moody AP; al-Khaffaf HS; Lehert P; Harris PL; Charlesworth D
J Cardiovasc Pharmacol; 1994; 23 Suppl 3():S44-7. PubMed ID: 7517477
[TBL] [Abstract][Full Text] [Related]
13. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS).
Kieffer E; Bahnini A; Mouren X; Gamand S
Int Angiol; 2001 Mar; 20(1):58-65. PubMed ID: 11342997
[TBL] [Abstract][Full Text] [Related]
14. Effects of ethaverine hydrochloride on the walking tolerance of patients with intermittent claudication.
Trainor FS; Phillips RE; Michie DD; Zellner SR; Hogan L; Chubb JM
Angiology; 1986 May; 37(5):343-51. PubMed ID: 3521401
[TBL] [Abstract][Full Text] [Related]
15. [Clinical effectiveness of naftidrofuryl in intermittent claudication].
Kriessmann A; Neiss A
Vasa Suppl; 1988; 24():27-32. PubMed ID: 3062823
[No Abstract] [Full Text] [Related]
16. [Placebo-controlled double-blind study of the effectiveness of Ginkgo biloba special extract EGb 761 in trained patients with intermittent claudication].
Blume J; Kieser M; Hölscher U
Vasa; 1996; 25(3):265-74. PubMed ID: 8967154
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK.
Guest JF; Davie AM; Clegg JP
Curr Med Res Opin; 2005 Jun; 21(6):817-26. PubMed ID: 15969881
[TBL] [Abstract][Full Text] [Related]
18. Randomized placebo-controlled, double-blind trial of ketanserin in claudicants. Changes in claudication distance and ankle systolic pressure. PACK Claudication Substudy.
Circulation; 1989 Dec; 80(6):1544-8. PubMed ID: 2688971
[TBL] [Abstract][Full Text] [Related]
19. The effect of naftidrofuryl on transcutaneous oxygen tension during a treadmill test in patients with peripheral arterial occlusive disease.
Mouren X; Caillard P; Bensoussan JJ; Massonneau M; Gamand S; Stevens WH
Vasc Med; 1998; 3(1):9-14. PubMed ID: 9666526
[TBL] [Abstract][Full Text] [Related]
20. Naftidrofuryl for intermittent claudication: a double-blind controlled trial.
Ruckley CV; Callam MJ; Ferrington CM; Prescott RJ
Br Med J; 1978 Mar; 1(6113):622. PubMed ID: 343869
[No Abstract] [Full Text] [Related]
[Next] [New Search]
